Regeneron Pharmaceuticals
REGN
Market cap $59.5B

561.55 USD

+4.99

0.90%

At close Aug 13, 4:00 PM EDT

After hours

562.00

+0.45

0.08%

1 day

0.90%

5 days

0.70%

1 month

-1.58%

3 months

-2.20%

6 months

-16.72%

Year to date

-21.48%

1 year

-51.52%

5 years

-8.08%

10 years

-2.19%

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,207

Healthcare Biotechnology

0

Funds holding %

of 7,338 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

14% more repeat investments, than reductions

Existing positions increased: 511 | Existing positions reduced: 448

7% more funds holding in top 10

Funds holding in top 10: 14 [Q4 2024] → 15 (+1) [Q1 2025]

0.9% less ownership

Funds ownership: 86.11% [Q4 2024] → 85.21% (-0.9%) [Q1 2025]

3% less call options, than puts

Call options by funds: $974M | Put options by funds: $1B

5% less first-time investments, than exits

New positions opened: 139 | Existing positions closed: 147

2% less funds holding

Funds holding: 1,297 [Q4 2024] → 1,265 (-32) [Q1 2025]

12% less capital invested

Capital invested by funds: $66.3B [Q4 2024] → $58.1B (-$8.28B) [Q1 2025]

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$580

3%

upside

Avg. target

$719

28%

upside

High target

$850

51%

upside

10 analyst ratings

7 positive

70%

3 neutral

30%

0 negative

0%

Truist Securities Srikripa Devarakonda	45%upside $812	Buy Maintained	11 Aug 2025
BMO Capital Evan David Seigerman	14%upside $640	Outperform Maintained	4 Aug 2025
Morgan Stanley Matthew Harrison	36%upside $761	Overweight Maintained	4 Aug 2025
RBC Capital Brian Abrahams	24%upside $695	Sector Perform Maintained	4 Aug 2025
Guggenheim Yatin Suneja	45%upside $815	Buy Maintained	4 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 29 articles about REGN published over the past 30 days

Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity

Regeneron's Q2 showed strong earnings and cash flow, driven by DUPIXENT's growth and operational discipline, despite EYLEA's ongoing revenue decline. EYLEA faces intense competition and margin pressure, but DUPIXENT's expanding indications and LIBTAYO's solid performance offset these headwinds. Regeneron's oncology pipeline is advancing, highlighted by LYNOZYFIC's approval, while strategic moves in obesity drugs aim for future growth.

Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity

These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings

On Friday, Regeneron Pharmaceuticals Inc. REGN reported upbeat second-quarter earnings.

These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings

The Motley Fool

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts

The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other products are often at the forefront of innovation in the healthcare space, a durable industry that tends to be broadly resilient even in times of economic unrest.

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts

The Motley Fool

Regeneron (REGN) Q2 EPS Jumps 53%

Regeneron (REGN) Q2 EPS Jumps 53%

Regeneron (REGN) Q2 EPS Jumps 53%

Regeneron: Rapidly Decreasing Importance Of Eylea

Regeneron Pharmaceuticals delivered strong Q2 results, driven by Dupixent and Libtayo growth that were enough to offset the decline of the Eylea franchise. The existing product portfolio and upcoming approvals should be more than sufficient to keep Regeneron in growth mode. The obesity pipeline expansion adds a new growth avenue for the company in the 2030s.

Regeneron: Rapidly Decreasing Importance Of Eylea

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO George D.

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Nonfarm Payrolls Come in SIgnificantly Below Expectations

Nonfarm Payrolls Come in SIgnificantly Below Expectations.

Nonfarm Payrolls Come in SIgnificantly Below Expectations

Zacks Investment Research

Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up

REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.

Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Zacks Investment Research

Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

See News Rankings

Charts implemented using Lightweight Charts™